Clinical Trial

Tricuspid Regurgitation Treatment With LAPLACE Transcatheter Tricuspid Valve Replacement System

Study acronym: TRIUMPH
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The objective of this clinical study is to assess the safety and efficacy of the Laplace Transcatheter Tricuspid Valve Replacement (TTVR) System for the treatment of symptomatic subjects with at least severe tricuspid regurgitation (TR).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-07-01.
Trial Details
NCT Number NCT07687485
Lead Sponsor Laplace Interventional, Inc
Conditions Severe Tricuspid Valve Regurgitation, Tricuspid Valve Regurgitation, Tricuspid Valve Disease, Cardiovascular Diseases (CVD), Heart Valve Diseases, Tricuspid Valve Insufficiency, Severe Heart Valve Disease, Symptomatic Tricuspid Regurgitation
Enrollment 700 participants
Start Date 2026-09
Primary Completion 2029-09 (estimated)
Study Completion 2038-09 (estimated)
Updated on ClinicalTrials.gov 2026-07-22